Sana Biotechnology to Present at March 2026 Investor Conferences

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update.

GlobeNewsWire • Feb 23, 2026

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.

Zacks Investment Research • Feb 20, 2026

Sana Biotechnology: A Small, Speculative Play

Sana Biotechnology pivots to focus on its SC451 hypoimmune cell therapy for type 1 diabetes, aiming for a functional cure. Recent single-patient data validate SANA's immune-evasion technology, driving a sharp rally but underscoring early-stage risk and manufacturing challenges. With a $1B valuation and limited cash runway to YE26, SANA will likely require further dilution to fund pivotal clinical trials.

Seeking Alpha • Feb 13, 2026

Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know

Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jan 30, 2026

Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet

The consensus price target hints at a 74.2% upside potential for Sana (SANA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Jan 23, 2026

Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips

SANA's thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451's planned 2026 IND is the primary catalyst going forward. In my view, this is their make-or-break catalyst this year. A favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a sizeable TAM in TD1.

Seeking Alpha • Jan 19, 2026

Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

GlobeNewsWire • Jan 7, 2026

Three Genomics Stocks Worth Tracking This Year

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.

Zacks Investment Research • Jan 6, 2026

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology

GlobeNewsWire • Dec 8, 2025